Search

Search Constraints

You searched for: Author/Creator Snider, B. Joy

Search Results

1. [P4–568]: PROSPECTIVE ESCITALOPRAM DECREASES LONGITUDINAL CSF Aβ CONCENTRATION IN COGNITIVELY NORMAL ELDERLY SUBJECTS: A RANDOMIZED DOSE FINDING STUDY. (1st July 2017)

2. Amyloid‐Related Imaging Abnormalities in the DIAN‐TU‐001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease. Issue 5 (13th October 2022)

3. Effect of escitalopram dose and treatment duration on CSF Aβ levels in healthy older adults: A controlled clinical trial. (10th November 2020)

4. Gantenerumab in‐depth outcomes: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. (7th December 2020)

6. O1‐10‐04: Escitalopram Decreases Longitudinal CSF ABETA Concentration in Cognitively Normal Subjects age 60‐85. (1st July 2016)

7. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab: Results of the DIAN‐TU prevention trial of solanezumab and gantenerumab in dominantly inherited AD. (7th December 2020)

9. P3‐026: DIFFERENTIAL EFFECT OF PROSPECTIVE ESCITALOPRAM DECREASE ON LONGITUDINAL CSF AB CONCENTRATION IN AMYLOID (+) VERSUS AMYLOID (‐) COGNITIVELY NORMAL ELDERLY INDIVIDUALS. (1st July 2006)

10. Reductions of the components of the calreticulin/calnexin quality‐control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease. Issue 10 (23rd May 2014)